You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》大和下調石藥(01093.HK)目標價至11.6元 評級「買入」
阿思達克 03-28 10:40
大和發表研究報告,指石藥集團(01093.HK)去年下半年純利16億元人民幣符預期。報告降其今明兩年收入預測4%至5%,因降國產新冠疫苗SYS6006今明兩年收入預測各至10億元人民幣。考慮到收入及毛利率預測下調,降石藥今明兩年盈測各10%,以現金流折現率計,目標價降9%至11.6元,評級「買入」。 報告稱,石藥現估值相當於今年預測市盈率11.6倍,每股盈利增長7%,或相當於預測市盈增長率1.6倍,低於同業平均的2倍。該行認為現估值不高,SYS6006銷售、RNA資產開發等或提供上行驚喜。公司指引撇除SYS6006今年料有正增長,原先去年11月時料今年收入及純利有雙位數增長,指引改變主因疫情干擾及宏觀不確定性。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account